PHA-022121

DRUG2 trials

Sponsors

Pharvaris Netherlands B.V.

Conditions

Hereditary angioedemaHereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II)

Phase 2

A Phase II/III, Extension Study of Orally Administered PHA-022121 for Acute Treatment of Angioedema Attacks in Patients with Hereditary Angioedema

RecruitingCTIS2023-505766-28-00

Pharvaris Netherlands B.V.Hereditary angioedema

Start: 2022-10-10Target: 74Updated: 2025-10-29

A Phase II, Double-blind, Placebo-controlled, Randomized, Dose-ranging, Parallel Group Study to Evaluate the Safety and Efficacy of PHA-022121 Administered Orally for Prophylaxis Against Angioedema Attacks in Patients with Hereditary Angioedema due to C1-Inhibitor Deficiency (Type I or Type II)

CompletedCTIS2023-505549-18-00

Pharvaris Netherlands B.V.Hereditary angioedema due to C1-Inhibitor Deficiency (Type I or Type II)

Start: 2022-04-29End: 2025-06-30Target: 21Updated: 2025-01-15